Abstract 1672P
Background
Waiting involves staying in a place until an expected event occurs. From diagnosis to follow-up and treatment, cancer patients (pts) often endure waiting. Understanding their emotions during this time is crucial. Few studies have explored the experiences and emotions of cancer pts in the waiting room (WR).
Methods
An anonymous 12-item online questionnaire was distributed to cancer pts in our center's WR. The questionnaire was divided into 3 sections including clinical and socio-demographic information, time spent in the WR, and pts considerations. The aim of this study was to investigate cancer pts’ emotions and behaviors in the WR.
Results
160 pts completed the questionnaire (48% women, 52% men). The most common age groups were 51-65 years old (37%) and 66-80 years old (41%). The majority of pts are unemployed (58.5%). About half of interviewed pts undergo infusion therapies and/or visit 1-2 times monthly. When asked to describe the wait duration, approximately half found it long (32%) or too long (17%). Pts spend this period on mobile phones (47%), watching TV (21%), reading or listening to music (16%), and conversing with others (11%). Both positive (49% calm, 7.5% hopeful, 5% emotional involvement) and negative (26% boredom, 21% anxiety, 6% sadness, 5% anger, 1% apathy) emotions were experienced. The multiple logistic regression model confirms the independent predictor role for a negative emotional status in the WR of a perceived long or too long waiting period (OR=4.0, p<0.001) and the independent role of protector of male gender (OR=0.4, p0.008). A trend of significance emerged for employment (OR=0.4, p0.052) and engaging in active behaviors (OR=0.4, p0.058) as protective factors. When asked how to improve the quality of time in the WR, 38% suggested live entertainment (music, readings, and cancer information), 26% preferred access to newspapers and magazines. The most requested topics are treatment news (51%), diet (46%), and physical activity (27%).
Conclusions
For cancer pts the waiting can be a meaningful experience. Many pts find the wait long, boring, and anxiety-provoking. Our experience suggests how active and externalizing behaviors are less linked to negative emotions and interactive activities could improve the quality of time spent in the WR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11